샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744892

세계의 트롬보엘라스토그래피 시장

Thromboelastography
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 390 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 트롬보엘라스토그래피 시장은 2030년까지 9억 3,310만 달러에 이를 전망

2024년에 6억 7,210만 달러로 추정되는 트롬보엘라스토그래피 세계 시장은 2024-2030년간 CAGR 5.6%로 성장하여 2030년에는 9억 3,310만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 표준 트롬보엘라스토그래피는 CAGR 7.3%를 나타내고, 분석 기간 종료시에는 2억 8,240만 달러에 이를 것으로 예측됩니다. Rapid TEG 부문의 성장률은 분석 기간에 CAGR 4.2%로 추정됩니다.

미국 시장은 1억 8,310만 달러로 추정, 중국은 CAGR 9.2%로 성장 예측

미국의 트롬보엘라스토그래피 시장은 2024년에 1억 8,310만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 9.2%로 성장하여 2030년에는 1억 9,100만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.6%와 5.6%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%를 보일 전망입니다.

세계의 '트롬보엘라스토그래피' 시장 - 주요 동향과 촉진요인 정리

혈전 엘라스토그래피가 중환자 치료에서 지혈 검사를 어떻게 재정의하고 있는가?

트롬보엘라스토그래피(TEG)는 전체 응고 과정을 동적으로 실시간으로 평가함으로써 기존의 응고 분석법을 넘어 임상의가 지혈을 평가하는 방식에 혁명을 일으키고 있습니다. 응고 캐스케이드의 고립된 지점을 평가하는 PT, aPTT, INR과 같은 기존 검사 항목과 달리 TEG는 혈전 형성, 안정화, 용해를 종합적으로 평가합니다. 이 실시간 평가는 혈액제제 투여에 대한 신속하고 정확한 결정이 생명을 구할 수 있는 외상, 심장 수술, 간 이식, 중환자실 환경에서 특히 유용합니다. TEG는 혈액이 응고될 때 점탄성 특성을 추적하여 출혈의 원인이 혈소판 기능 장애, 피브리노겐 결핍 또는 선천성 용혈로 인한 것인지 여부를 파악할 수 있습니다. 그 결과, 혈소판, 혈장, 냉동혈소판의 불필요한 사용을 줄이면서 환자의 예후를 개선하는 맞춤형 수혈 전략을 수립할 수 있습니다. 수혈 관련 합병증(TRALI, 면역 변조증 등)의 위험에 대한 인식이 높아짐에 따라 병원들은 보다 정확하고 표적화된 응고 모니터링을 채택하고 있으며, TEG 시스템은 이러한 환자 맞춤형 지혈 요법으로의 전환에 있어 유력한 기술로 부상하고 있습니다.

혈전 엘라스토그라피가 외과 및 응급의료의 새로운 표준이 될 수 있을까?

혈전 탄성파 검사의 임상적 범용성은 출혈성 합병증이 흔하고, 촌각을 다투는 결정이 필수적인 수술 및 응급 의료 분야에서 새로운 표준 치료법으로 자리매김하고 있습니다. TEG는 응고 이상이 복잡하고 다인자적인 경우가 많은 심장 및 간 수술에서 소모성 응고 이상과 희석성 응고 이상을 구분하는 데 필요한 세밀함을 제공하여 정확한 개입을 가능하게 합니다. 와파린, DOAC, 헤파린 등 항응고 치료를 받는 환자 관리에서 TEG의 유용성은 수술 전 선별검사와 수술 중 모니터링 모두에서 유용한 도구가 될 수 있습니다. 응급실에서도 TEG를 외상 환자 관리에 활용하고 있으며, TEG의 통찰력을 바탕으로 대량 수혈 프로토콜을 최적화하여 이환율과 사망률을 모두 감소시키고 있습니다. 산부인과 센터에서는 분만 후 출혈, 특히 자간전증 및 HELLP 증후군의 경우 출혈 위험을 평가하기 위해 TEG를 사용하고 있습니다. 중환자실(ICU)에서는 패혈증, 파종성 혈관 내 응고 증후군(DIC), 코로나19 관련 응고 장애 환자의 지속적인 응고 평가에 TEG를 도입하고 있습니다. 의료 분야 전반에 걸친 광범위한 적용 가능성과 데이터 기반의 신속한 의사결정에 대한 요구는 TEG를 이용한 실시간 응고 진단으로의 전환을 촉진하고 있습니다.

트롬보 엘라스토그라피는 어떤 기술적 강화를 통해 역량을 확장하고 있는가?

최근 트롬보 엘라스토그래피 기술의 발전은 시스템을 보다 사용하기 쉽고, 정확하며, 다양한 임상 환경에 적응할 수 있는 시스템을 만들었습니다. 최신 TEG 분석기는 자동화된 시료 처리, 터치스크린 인터페이스, 통합된 품질 관리 기능을 갖추고 있어 기술자의 실수를 줄이고 안정적인 결과를 얻을 수 있습니다. 휴대용 및 현장 진료(POC) TEG 시스템은 실시간 응고 모니터링에 대한 접근성을 3차 병원뿐만 아니라 소규모 수술센터, 구급차 및 야전 병원으로 확장하고 있습니다. 소프트웨어 업그레이드를 통해 고급 분석, 클라우드 기반 데이터 공유, 전자 의료 기록(EHR)과의 통합이 가능해져 결과를 신속하게 해석하여 다학제 치료에 효과적으로 활용할 수 있게 되었습니다. 카트리지형 검사 시스템도 있어 수작업 피펫팅의 필요성을 없애고, 감염 발생 시 생물학적 안전성을 강화했습니다. 제조업체들은 또한 진단의 특이성을 높이고 항응고제 역전 전략을 안내하기 위해 다중 분석 및 바이오마커 통합을 모색하고 있습니다. 이러한 강화는 임상 교육 및 알고리즘 기반 의사 결정 지원 도구 증가와 함께 학습 곡선을 줄이고 임상의가 실시간 치료 결정에 TEG 통찰력을 통합하여 점점 더 다양해지는 의료 환경에서 TEG의 유용성을 확대할 수 있도록 돕고 있습니다.

트롬보 엘라스토그래피 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

혈전 엘라스토그래피의 채택이 증가하는 주요 요인은 고위험 수술, 외상 치료 및 중증 환자 관리에서 혈전 엘라스토그래피의 임상적 중요성이 증가하고 있기 때문입니다. 전 세계적으로 심혈관 질환, 간 질환, 외상(특히 신흥국)의 부담이 증가함에 따라 지혈 평가 및 수혈 관리에 대한 보다 정확한 도구가 필요합니다. 또한, 수술 건수 증가와 최소침습 수술의 복잡성이 증가함에 따라 정확한 수술 중 응고 모니터링의 필요성이 증가하고 있습니다. 병원은 비용 절감과 수혈 관련 합병증 방지라는 두 가지 측면에서 혈액제제 사용량을 줄여야 하는 상황으로, TEG와 같은 정밀 유도 수혈 전략에 대한 요구가 증가하고 있습니다. 이와 함께, 고령화 사회에서의 항응고 요법과 복잡한 응고 이상 유병률 증가는 응고 상태를 실시간으로 정확하게 평가할 수 있는 기술에 대한 수요를 창출하고 있습니다. 또한, 현장 검사 트렌드와 진단 서비스의 분산화로 인해 TEG는 대형병원에서 외래 수술센터와 응급실까지 확대되고 있습니다. 자동화, 휴대성, EHR 통합과 같은 기술 발전은 사용 편의성을 향상시키고 운영상의 장벽을 낮추고 있습니다. 한편, 규제 당국의 승인과 임상 가이드라인의 승인은 현대의 임상 워크플로우에서 TEG의 가치를 강화하고 있습니다. 기술, 의료 서비스 제공 및 환자 인구 통계 분야의 이러한 역학의 수렴은 세계 혈전 엘라스토그래피 시장의 급격한 성장을 가속하고 있습니다.

부문

유형(표준, 신속 TEG, 네이티브 TEG, 헤파리나아제, 기능성 섬유소원, 혈소판 매핑); 애플리케이션(심폐 바이패스, 간 수술, 외상 수술, 산부인과); 최종 사용자(병원, 혈액 은행, 학술 기관, 기타 최종 사용자)

조사 대상 기업 예(총 42개사)

  • 5-Diagnostics GmbH
  • Bio-Zircon
  • Biomart
  • Chongqing Dingrun
  • Chongqing Nanfang
  • Diagnostica Stago
  • Framar Hemologix Srl
  • Guizhou Jinjiu Biotech
  • Haemonetics Corporation
  • HemaCore LLC
  • Instrumentation Laboratory(Werfen)
  • Lepu Medical Technology
  • Medcaptain Medical Technology
  • Medirox AB
  • Render Biotech Co., Ltd.
  • Sienco, Inc.
  • SYCOmed e.K.
  • Ud-Bio
  • WerfenLife
  • WITEYE

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

각국의 최종 리셋이 발표되는 7월에도 고객님들께 무료 업데이트를 제공할 예정입니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.19

Global Thromboelastography Market to Reach US$933.1 Million by 2030

The global market for Thromboelastography estimated at US$672.1 Million in the year 2024, is expected to reach US$933.1 Million by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Standard Thromboelastography, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$282.4 Million by the end of the analysis period. Growth in the Rapid TEG segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$183.1 Million While China is Forecast to Grow at 9.2% CAGR

The Thromboelastography market in the U.S. is estimated at US$183.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$191.0 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global "Thromboelastography" Market - Key Trends & Drivers Summarized

How Is Thromboelastography Redefining Hemostasis Testing in Critical Care?

Thromboelastography (TEG) is revolutionizing how clinicians assess hemostasis, moving beyond traditional coagulation assays by providing a dynamic, real-time evaluation of the entire clotting process. Unlike conventional lab tests such as PT, aPTT, or INR, which assess isolated points of the coagulation cascade, TEG offers a comprehensive view of clot formation, stabilization, and dissolution. This real-time assessment is especially valuable in trauma, cardiac surgery, liver transplantation, and intensive care settings, where rapid and accurate decisions about blood product administration can be life-saving. By tracking the viscoelastic properties of blood as it clots, TEG enables clinicians to pinpoint whether bleeding is due to platelet dysfunction, fibrinogen deficiency, or hyperfibrinolysis. The result is a personalized transfusion strategy that reduces unnecessary use of platelets, plasma, and cryoprecipitate, while improving patient outcomes. Increasing awareness of the risks of transfusion-related complications-such as TRALI and immunomodulation-is pushing hospitals to adopt more precise, targeted coagulation monitoring, and TEG systems are emerging as the go-to technology in this shift toward patient-specific hemostatic therapy.

Can Thromboelastography Become the New Standard in Surgical and Emergency Medicine?

The clinical versatility of thromboelastography is positioning it as a new standard of care in surgical and emergency medicine environments where bleeding complications are common and time-critical decisions are essential. In cardiac and liver surgeries, where coagulopathies are often complex and multi-factorial, TEG provides the granularity needed to distinguish between consumptive and dilutional coagulopathy, enabling precise intervention. Its utility in managing anticoagulated patients-whether on warfarin, DOACs, or heparin-makes it a valuable tool in both preoperative screening and intraoperative monitoring. Emergency departments are also turning to TEG in the management of trauma patients, where massive transfusion protocols can be optimized based on TEG-guided insights, reducing both morbidity and mortality. Obstetric centers are using TEG to assess bleeding risk in cases of postpartum hemorrhage, especially in preeclampsia and HELLP syndrome. Meanwhile, intensive care units (ICUs) are incorporating TEG for ongoing coagulation assessment in patients with sepsis, disseminated intravascular coagulation (DIC), or COVID-19-associated coagulopathy. The widespread applicability across medical disciplines and the demand for faster, data-driven decisions are driving a shift toward real-time coagulation diagnostics powered by TEG.

What Technological Enhancements Are Expanding the Capabilities of Thromboelastography?

Recent advancements in thromboelastography technology are making the systems more user-friendly, accurate, and adaptable to various clinical settings. Modern TEG analyzers feature automated sample handling, touch-screen interfaces, and integrated quality controls, reducing technician error and enabling consistent results. Portable and point-of-care (POC) TEG systems are expanding access to real-time coagulation monitoring beyond tertiary hospitals into smaller surgical centers, ambulances, and field hospitals. Software upgrades now allow for advanced analytics, cloud-based data sharing, and integration into electronic health records (EHRs), ensuring that results can be interpreted quickly and used effectively in multidisciplinary care. Some systems offer cartridge-based testing, eliminating the need for manual pipetting and enhancing biosafety during infectious disease outbreaks. Manufacturers are also exploring multiplexed assays and biomarker integration to improve diagnostic specificity and guide anticoagulant reversal strategies. Coupled with increased clinical training and algorithm-based decision support tools, these enhancements are reducing the learning curve and helping clinicians incorporate TEG insights into real-time therapeutic decisions, thereby expanding its utility across increasingly diverse healthcare environments.

The Growth in the Thromboelastography Market Is Driven by Several Factors…

The rising adoption of thromboelastography is primarily driven by its growing clinical relevance in high-risk surgical specialties, trauma care, and critical illness management. The increasing global burden of cardiovascular disease, liver disorders, and trauma cases-particularly in emerging economies-is necessitating more precise tools for hemostasis assessment and transfusion management. Additionally, as surgical volumes rise and minimally invasive procedures become more complex, the need for accurate intraoperative coagulation monitoring is intensifying. Hospitals are under pressure to reduce blood product usage both for cost containment and to avoid transfusion-related complications, pushing demand for precision-guided transfusion strategies like those enabled by TEG. In parallel, the rising prevalence of anticoagulant therapy and complex coagulopathies in aging populations is creating a need for technologies that can accurately evaluate clotting status in real time. Point-of-care testing trends and the decentralization of diagnostic services are also expanding TEG adoption beyond large hospitals to ambulatory surgical centers and emergency response units. Technological advancements-such as automation, portability, and EHR integration-are enhancing usability and reducing operational barriers, while regulatory approvals and clinical guideline endorsements are reinforcing TEG’s value in modern clinical workflows. These converging dynamics across technology, healthcare delivery, and patient demographics are propelling the rapid growth of the global thromboelastography market.

SCOPE OF STUDY:

The report analyzes the Thromboelastography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen, Platelet Mapping); Application (Cardiopulmonary Bypass, Liver Surgery, Trauma Surgery, Obstetrics); End-User (Hospitals, Blood Banks, Academic Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 5-Diagnostics GmbH
  • Bio-Zircon
  • Biomart
  • Chongqing Dingrun
  • Chongqing Nanfang
  • Diagnostica Stago
  • Framar Hemologix Srl
  • Guizhou Jinjiu Biotech
  • Haemonetics Corporation
  • HemaCore LLC
  • Instrumentation Laboratory (Werfen)
  • Lepu Medical Technology
  • Medcaptain Medical Technology
  • Medirox AB
  • Render Biotech Co., Ltd.
  • Sienco, Inc.
  • SYCOmed e.K.
  • Ud-Bio
  • WerfenLife
  • WITEYE

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Thromboelastography - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Surgical Procedures Drive Demand for Real-Time Hemostasis Testing
    • Rise in Trauma Cases and Critical Care Settings Strengthens Product Utilization
    • Rapid Adoption in Cardiovascular Surgery Expands Market Footprint
    • Personalized Medicine Initiatives Propel Growth of Point-of-Care Coagulation Analysis
    • Shift Toward Comprehensive Coagulation Profiling Drives Technological Innovation
    • Growing Use in Postpartum Hemorrhage and Liver Transplant Cases Broadens Applications
    • Clinical Evidence Supporting Improved Outcomes Spurs Adoption
    • Integration with Hospital EMR Systems Enhances Workflow Efficiency
    • Expanding Role in Anticoagulant Monitoring Increases Device Penetration
    • Training and Awareness Initiatives Drive Usage in Low-Penetration Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Thromboelastography Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Thromboelastography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rapid TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rapid TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Rapid TEG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Native TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Native TEG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Native TEG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Heparinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Heparinase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Heparinase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Functional Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Functional Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Functional Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Platelet Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Platelet Mapping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Platelet Mapping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Obstetrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Obstetrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Obstetrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiopulmonary Bypass by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiopulmonary Bypass by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cardiopulmonary Bypass by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Liver Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Liver Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Liver Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Trauma Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Trauma Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Trauma Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • JAPAN
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • CHINA
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • EUROPE
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Thromboelastography by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • FRANCE
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • GERMANY
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Thromboelastography by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • INDIA
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Thromboelastography by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Thromboelastography by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Thromboelastography by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030
  • AFRICA
    • Thromboelastography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Thromboelastography by Type - Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Thromboelastography by Type - Percentage Breakdown of Value Sales for Standard, Rapid TEG, Native TEG, Heparinase, Functional Fibrinogen and Platelet Mapping for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Thromboelastography by Application - Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Thromboelastography by Application - Percentage Breakdown of Value Sales for Obstetrics, Cardiopulmonary Bypass, Liver Surgery and Trauma Surgery for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Thromboelastography by End-user - Hospitals, Blood Banks, Academic Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Thromboelastography by End-user - Percentage Breakdown of Value Sales for Hospitals, Blood Banks, Academic Institutes and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제